Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Promise for AC Immune's neurodegenerative programs
June 2020
SHARING OPTIONS:

LAUSANNE, Switzerland—This April saw the first-ever online AAT-AD/PD Focus Meeting, at which biopharmaceutical company AC Immune SA shared preclinical proof-of-concept data for its lead candidates in programs targeting TDP-43 and alpha-synuclein. The preclinical studies detail the use of AC Immune's technology platforms—SupraAntigen and Morphomer—in developing candidates to target pathologies linked to TDP-43 and alpha-synuclein. Antibody candidates demonstrated the ability to mitigate TDP-43 neuropathology, the ability to bind to TDP-43 and reducing the formation of alpha-synuclein aggregates in vitro, among other results.
 
“AC Immune continues to deliver on its Roadmap to Successful Therapies for Neurodegenerative Diseases, enabling precision medicine by selecting clinical study populations based on the presence of the underlying proteinopathies,” said Prof. Andrea Pfeifer, CEO of AC Immune.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.